Stock AnalizHinge Health, Inc. HNGE
EDP Services · IPO 2025 · data as of November 13, 2026
Hinge Health, Inc. (HNGE) is a technology company listed in the US with a market value of about $9.4B. In the twelve months to September 30, 2026 it had revenue of $801M and net income of $168M, a net margin of 21.0%.
Its overall Stock Analiz score is 1.6 out of 5 (weak). The strongest part is financial health (4/5); the weakest is track record (0/5).
Key numbers: a P/E of 31.2, a price to free cash flow of 29.1, a 5-year average ROIC of -231%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 34% above the current price.
Score: 1.6 / 5
Checks passed
- Price below intrinsic value (DCF, moderate assumptions)
- Revenue growth above 10% last year
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Positive free cash flow
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
- 20% to 100% of free cash flow returned to shareholders
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- PEG below 1.5
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 3 years
| Fiscal year | TTM | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Revenue | $801M | $588M | $390M | $293M |
| Net income | $168M | -$528M | -$12M | -$108M |
| Free cash flow | $322M | $171M | $48M | -$66M |
| EPS (diluted) | $3.70 | $-7.77 | $-0.88 | $-8.31 |
| Net margin | 21.0% | -89.9% | -3.1% | -36.9% |
| ROIC | — | -231.2% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 16 analysts is $135.38, 17% above the current price; targets range from $90.00 to $151.00; the consensus rating is “Buy”; expected EPS is $2.57 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Hinge Health’s P/E ratio?
About 31.2, based on the last twelve months of diluted earnings per share (forward P/E about 38.4).
Is Hinge Health stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 34% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Hinge Health pay a dividend?
Not currently.
Is Hinge Health a good stock to buy?
We do not give buy or sell advice. Hinge Health scores 1.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.